EXPRESSION OF ALU REPEAT IN BLOOD PLASMA OF PATIENTS WITH BREAST CANCER DURING NEOADJUVANT CHEMOTHERAPY: AN EXPLORATORY STUDY

Authors

  • E. Özgür Department of Basic Oncology, Oncology Institute, Istanbul University, Istanbul 34093, Turkey
  • F. Ferhatoglu Department of Medical Oncology, Oncology Institute, Istanbul University, Istanbul 34093, Turkey
  • F. Sen Department of Medical Oncology, Oncology Institute, Istanbul University, Istanbul 34093, Turkey
  • P. Saip Department of Medical Oncology, Oncology Institute, Istanbul University, Istanbul 34093, Turkey
  • U. Gezer Department of Basic Oncology, Oncology Institute, Istanbul University, Istanbul 34093, Turkey

DOI:

https://doi.org/10.15407/exp-oncology.2023.01.120

Keywords:

ALU expression, locally advanced breast cancer, menopausal status, neoadjuvant chemotherapy

Abstract

Background:Locally advanced breast cancer (LABC) rates are unusually high in developing countries. There is a need for the identification of predictive biomarkers for the selection of patients who could benefit from neoadjuvant chemotherapy (NAC). Aim: As the expression of ALU repeat is increased in cancer and has not been assessed in liquid biopsy of cancer patients, our goal was to assess ALU expression in the blood plasma of LABC patients during NAC. Patients and Methods:Plasma samples drawn at baseline and at the end of the fourth cycle of chemotherapy were used to determine the plasma levels of ALU-RNA by quantitative real-time PCR. Results: ALU expression from baseline to the fourth cycle of NAC increased from a median relative level of 1870 to 3370 in the whole group (p = 0.03). The increase in ALU-RNA levels in the course of NAC was more pronounced in premenopausal women and in patients with hormone-positive tumors. In patients with complete response to NAC, baseline ALU expression was higher than that in those with partial response. Conclusion: This exploratory study provides evidence that plasma ALU-RNA levels are modulated by the menopausal status and hormone receptor status of breast cancer patients and pre-therapeutic ALU-RNA levels might be useful in predicting the response to chemotherapy in a neoadjuvant setting.

References

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249. doi: 10.3322/caac.21660

Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144: 1941–1953. doi: 10.1002/ijc.31937

Özmen V. Breast cancer in Turkey: clinical and histopathological characteristics (analysis of 13.240 Patients). J Breast Health 2014; 10: 98–105. doi: 10.5152/tjbh.2014.1988

Simos D, Clemons M, Ginsburg OM, et al. Definition and consequences of locally advanced breast cancer. Curr Opin Support Palliat Care 2014; 8: 33–38. doi: 10.1097/SPC.0000000000000020

Çakmak GK, Emiroğlu S, Sezer A, et al. Surgical trends in breast cancer in Turkey: an increase in breast-conserving surgery. JCO Glob Oncol 2020; 6: 285–292. doi: 10.1200/JGO.19.00275

Bedwinek J, Rao DV, Perez C, et al. Stage III and localized stage IV breast cancer: irradiation alone vs irradiation plus surgery. Int J Radiat Oncol Biol Phys 1982; 8: 31–36. doi:10.1016/0360-3016(82)90381-9

Valagussa P, Zambetti M, Bignami P, et al. T3b-T4 breast cancer: factors affecting results in combined modality treatments. Clin Exp Metastasis 1983; 1: 191–202. doi:10.1007/BF00121498

Huang EH, Tucker SL, Strom EA, et al.Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62: 351–357. doi:10.1016/j.ijrobp.2004.09.056

Meyers MO, Klauber-Demore N, Ollila DW, et al. Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol 2011; 18: 2851–2857. doi: 10.1245/s10434-011-1665-8

Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg 2014; 260: 608–614. doi: 10.1097/SLA.0000000000000924

Rouzier R, Pusztai L, Delaloge S, et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 2005; 23: 8331-8339. doi: 10.1200/JCO.2005.01.2898

Katayama A, Miligy IM, Shiino S, et al. Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. Mod Pathol 2021; 34: 1271–1281. doi: 10.1038/s41379-021-00738-5

De Freitas AJA, Causin RL, Varuzza MB, et al. Molecular biomarkers predict pathological complete response of neoadjuvant chemotherapy in breast cancer patients: review. Cancers (Basel) 2021; 13: 5477. doi: 10.3390/cancers13215477

Zhang W, Edwards A, Fan W, et al. Alu distribution and mutation types of cancer genes. BMC Genomics 2011; 12: 157. doi: 10.1186/1471-2164-12-157

Cantarella S, Di Nisio E, Carnevali D, et al. Interpreting and integrating big data in non-coding RNA research. Emerg Top Life Sci 2019; 3: 343–355. doi: 10.1042/ETLS20190004

Jordà M, Díez-Villanueva A, Mallona I, et al. The epigenetic landscape of Alu repeats delineates the structural and functional genomic architecture of colon cancer cells. Genome Res 2017; 27: 118-132. doi: 10.1101/gr.207522.116

Downloads

Published

26.06.2023

How to Cite

Özgür, E., Ferhatoglu, F., Sen, F., Saip, P., & Gezer, U. (2023). EXPRESSION OF ALU REPEAT IN BLOOD PLASMA OF PATIENTS WITH BREAST CANCER DURING NEOADJUVANT CHEMOTHERAPY: AN EXPLORATORY STUDY. Experimental Oncology, 45(1), 120–124. https://doi.org/10.15407/exp-oncology.2023.01.120

Issue

Section

Short communications